List of Microbiome Companies in Spain - 6

AB-BIOTICS is a leading probiotics player inspired by developing probiotic solutions at the forefront of an expanding field. Whether you are interested in unique, patented strains with characterized mechanisms of action, premium probiotic solutions targeting specific therapeutic areas, or finished products with easily-communicated benefits, our agile approach allows us to adapt to your needs. With science at the heart of everything we do, our strains, blends and market-ready products are supported by robust scientific documentation. Our global footprint gives us a unique view of the ever-changing probiotic landscape enabling us to offer regulatory support in not only supplements, and functional foods but also OTC and medical applications to meet the needs of consumers worldwide.

Microviable Therapeutics is a biotech company at pre-clinical stage, developing novel biological drugs based on the microbiome to address unmet challenges in infectious diseases, oncology and dermatology. Microviable´s PharmaBiota® platform and proprietary technology has enabled to generate two different product categories, complete microbiota ecosystem products and defined bacterial consortia based on our large and diverse bacterial strain collection. Microviable´s proprietary technology and derived biological drugs have been protected through patents, trade secrets and trademarks with a growing portfolio of IP. Our lead candidate MVT-201 is a donor-derived complete microbiota ecosystem, with preclinical testing already finalized, that will enter clinical trials in 2024 for a multi-drug resistant infectious disease. Additionally, two other products are currently being developed with preliminary in vitro data available. Microviable has consolidated clinical and research international collaborations to be at the forefront of the microbiome science. Microviable is seeking to stablish collaboration agreements with pharma and biotech companies to license the biological drugs being developed, as well as other potential collaborations to further strength our capabilities in strategic therapeutic areas of interest. Microviable was incorporated in 2016, as a spinoff of the Spanish National Research Council (CSIC), founded by five prestigious research scientist and a business development person with extensive experience in pharmaceutical companies. Microviable has 10 high-qualified employees, it has received the European Seal of Excellence two times, numerous national and regional awards, and the certificate of Innovative SME. www.microviable.com

Mikrobiomik is a bio-pharmaceutical company founded to conduct research into and develop medicines based on the human microbiome. Our vision We aspire to be the first company in the world to market a medicine based on faecal microbiota in the EU. To that end, we are holding talks with both the EMA (European Medicines Agency) and the AEMPS (Spanish Agency for Medicines and Health Products) with a view to establishing protocols on the regulatory requirements for securing an MAA (Marketing Authorization Application) via centralised procedure. Our values Mikrobiomik seeks to lead the paradigm shift entailed by designing therapeutic solutions based on the human microbiome through excellence in its processes, empathising with chronic patients for whom no curative treatments are available, always from the perspective of networking with all stakeholders in the sector.

Sandwalk BioVentures is an end-to-end innovation, strategy, regulatory intelligence and management consulting firm that provides tailored, turnkey solutions to life sciences companies and investors. Specializing in the field of microbiome science, we help food and biopharma start-ups take technologies and products to market by supporting them with corporate, regulatory and commercial affairs, as well as larger corporations and investment firms find meaningful, evidence-based and data-driven market insights to make informed investment and M&A decisions. We are particularly focused on enabling non-EU companies establish, navigate the regulations and market their products in the EU, as well as on supporting EU companies in their regulatory efforts in the US. What makes Sandwalk special is its team’s profound understanding of the science and extensive industry experience. This enables us to go beyond advisory and add value by actively engaging with our partners in the execution of their projects. The "sandwalk" is the path behind Charles Darwin’s Down House near Kent in the UK, where he lived with his family from 1842 until his death in 1882. Down House provided Darwin with the peace and privacy he needed to mature his theories of evolution and natural selection, run his numerous experiments and write most of his works, including his most celebrated On the Origin of Species. The sandwalk was Darwin’s thinking path, around which he made regular circuits several times a day to think about science. "Sandwalk" therefore perfectly captures our essence and way of working: a systematic methodology, based on the thorough assessment of the science, to bring disruptive innovations to life.

Sequentia Biotech, an innovative bioinformatics firm, has been at the forefront of genomics since its establishment in 2013. Renowned for its cutting-edge solutions, Sequentia excels in providing comprehensive bioinformatics and software solutions across a spectrum of fields, including diagnostics, drug discovery, medical and academic research, plant biology, and food technologies. With a remarkable 15 years of experience in bioinformatics and significant investments in Research and Development (R&D), Sequentia has successfully completed over 700 bioinformatics projects. Serving clients in 63 countries, the company has contributed to over 70 publications in esteemed journals, showcasing an impressive H-index of 130. This outstanding track record underscores Sequentia's commitment to excellence. The company's overarching vision is to foster innovation and introduce disruptive technologies in the biotechnology landscape. By leveraging the potential of omics sciences, Sequentia aims to make meaningful contributions to society. Partner with Sequentia as they strive to shape a future where global advancements in biotechnology have a positive and transformative impact on lives.

Telum Therapeutics SL is a global drug discovery biotechnology company specializing in the use of Innovative Phage Lytic Proteins as antibiotics.